The new medicine of DNA repair pathways: damage repair vulnerabilities in cancer
Loss of DNA repair pathways is an early and frequent event in tumorigenesis. DNA repair-deficient cancers often become critically dependent on backup DNA repair pathways, which present an 'Achilles heel' that can be targeted to eliminate cancer cells.
This is the basis of synthetic lethality and is exemplified by the success of poly(ADP-ribose) polymerase (PARP) inhibitors in treating BRCA-deficient breast and ovarian cancers. However, new therapeutic strategies are urgently needed to overcome acquired and innate PARP inhibitor resistance and to exploit other DNA repair deficiencies. This meeting will discuss the discovery, development, success and clinical challenges of PARP inhibitors and the current efforts to develop new DNA repair inhibitors to exploit other vulnerabilities in cancer.
For the full programme, see below.
This event has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 3 category 1 (external) CPD credits.